The fate of lipoprotein cholesterol entering the arterial wall

Current Opinion in Lipidology

Volumn 8, Issue 5, 1997, Pages 246-252

  Kruth, Howard S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 OXOCHOLESTEROL; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CERAMIDE; CHOLESTEROL; CHYMASE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE; SIALIC ACID;

ARTERY WALL; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; FOAM CELL; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; MAST CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

EID: 0030864243     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199710000-00002     Document Type: Review

References (68)

1. Ball RY, Stowers EC, Burton JH, Cary NR, Skepper JN, Mitchinson MJ: Evidence that the death of macrophage foam cells contributes to the lipid core of atheroma. Atherosclerosis 1995, 114:45-54.
2. Bjorkerud S, Bjorkerud B: Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol 1996, 149:367-380.
3. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M: Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Nat Acad Sci USA 1995, 92:8264-8268.
4. Smith EB, Slater RS, Chu PK: The lipids in raised fatty and fibrous lesions in human aorta. A comparison of the changes at different stages of development. J Atheroscler Res 1968, 8:399-419.
5. Guyton JR, Klemp KF: Development of the atherosclerotic core region. Chemical and ultrastructural analysis of microdissected atherosclerotic lesions from human aorta. Arterioscler Thromb 1994, 14:1305-1314.
6. Guyton JR, Klemp KF: The lipid-rich core region of human atherosclerotic fibrous plaques. Prevalence of small lipid droplets and vesicles by electron microscopy. Am J Pathol 1989, 134:705-717.
7. Hollander W, Paddock J, Colombo M: Lipoproteins in human atherosclerotic vessels. I. Biochemical properties of arterial low density lipoproteins, very low density lipoproteins, and high density lipoproteins. Exp Mol Pathol 1982, 42:144-171.
8. Hoff HF, Gaubatz JW: Isolation, purification, and characterization of a lipoprotein containing apoB from the human aorta. Atherosclerosis 1982, 42:273-297.
9. Chao FF, Blanchette-Mackie EJ, Chen YJ, Dickens BF, Berlin E, Amende LM, Skarlatos SI, Gamble W, Resau JH, Mergner WT, Kruth HS: Characterization of two unique cholesterol-rich lipid particles isolated from human atherosclerotic lesions. Am J Pathol 1990, 136:169-179.
10. Gaynor PM, Zhang WY, Salehizadeh B, Pettiford B, Kruth HS: Cholesterol accumulation in human cornea: evidence that extracellular cholesteryl ester-rich lipid particles deposit independently of foam cells. J Lipid Res 1996, 37:1849-1861. The cornea accumulates cholesteryl ester-rich lipid particles larger than LDL and similar to lipid particles in the lipid core of human atherosclerotic lesions. As there are no macrophages in normal human corneas, this type of lipid particle is likely derived from fused LDL and not from lipid droplets released from foam cells.
11. Proctor SD, Mamo JC: Arterial fatty lesions have increased uptake of chylomicron remnants but not low-density lipoproteins. Coron Artery Dis 1996, 7:239-245.
12. Rapp JH, Lespine A, Hamilton RL, Colyvas N, Chaumeton AH, Tweedie-Hardman J, Kotite L, Kunitake ST, Havel RJ, Kane JP: Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 1994, 14:1767-1774.
13. Piha M, Lindstedt L, Kovanen PT: Fusion of proteolyzed low-density lipoprotein in the fluid phase: a novel mechanism generating atherogenic lipoprotein particles. Biochemistry 1995, 34:10120-10129.
14. Paananen K, Saarinen J, Annila A, Kovanen PT: Proteolysis and fusion of low density lipoprotein particles strengthen their binding to human aortic proteoglycans. J Biol Chem 1995, 270:12257-12262.
15. Schissel SL, Tweedie-Hardman J, Rapp JH, Graham G, Williams KJ, Tabas I: Rabbit aorta.and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest 1996, 98:1455-1464. This research group has previously shown that sphingomyelinase causes LDL to aggregate. Now it has been shown that release of ceramide from sphingomyelin mediates this aggregation. Further, the potential for such a mechanism to operate in atherosclerotic lesions was shown. It was determined that in comparison with plasma LDL, aggregated LDL isolated from lesions is enriched in ceramide. Also, incubation of LDL with strips of rabbit aorta caused some LDL to be retained in the strips, and only the retained LDL showed hydrolysis of sphingomyelin to ceramide.
16. 2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene. J Biol Chem 1996, 271:18431-18436
17. Tertov VV, Sobenin IA, Orekhov AN: Similarity between naturally occurring modified desialylated, electronegative and aortic low density lipoprotein. Free Rad Res 1996, 25:313-319.
18. Nielsen LB, Stender S, Kjeldsen K, Nordestgaard BG: Specific accumulation of lipoprotein (a) in balloon-injured rabbit aorta in vivo. Circ Res 1996, 78:615-626.
19. Nordestgaard BG, Wootton R, Lewis B: Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol 1995, 15:534-542.
20. Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J: Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 1996, 124:261-271.
21. Auerbach BJ, Bisgaier CL, Wolle J, Saxena U: Oxidation of low density lipoproteins greatly enhances their association with lipoprotein lipase anchored to endothelial cell matrix. J Biol Chem 1996, 271:1329-1335. Aging of LDL greatly increases its binding to lipoprotein lipase, thus possibly contributing to the retention of LDL to matrix-bound lipoprotein lipase in atherosclerotic lesions.
22. Carmena R, Ascaso JF, Camejo G, Varela G, Hurt-Camejo E, Ordovas JM, Martinez-Valls J, Bergstom M, Wallin B: Effect of olive and sunflower oils on low density lipoprotein level, composition, size, oxidation and interaction with arterial proteoglycans. Atherosclerosis 1996, 125:243-255.
23. Wiklund O, Bondjers G, Wright I, Camejo G: Insoluble complex formation between LDL and arterial proteoglycans in relation to serum lipid levels and effects of lipid lowering drugs. Atherosclerosis 1996, 119:57-67.
24. Aviram M, Maor I, Keidar S, Hayek T, Oiknine J, Bar-El Y, Adler Z, Kertzman V, Milo S: Lesioned low density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated. Biochem Biophys Res Commun 1995, 216:501-513.
25. Pentikainen MO, Lehtonen EM, Kovanen PT: Aggregation and fusion of modified low density lipoprotein. J Lipid Res 1996, 37:2638-2649. LDL fusion and aggregation may contribute to retention of this lipoprotein in the extracellular matrix of atherosclerotic lesions. This is a systematic study of the effects of many chemical modifications of LDL on LDL fusion and aggregation.
26. Mora R, Simionescu M, Simionescu N: Purification and partial characterization of extracellular liposomes isolated from the hyperlipidemic rabbit aorta. J Lipid Res 1990, 31:1793-1807.
27. Chao FF, Blanchette-Mackie EJ, Tertov VV, Skarlatos SI, Chen YJ, Kruth HS: Hydrolysis of cholesteryl ester in low density lipoprotein converts this lipoprotein to a liposome. J Biol Chem 1992, 267:4992-4998
28. Shamir R, Johnson WJ, Morlock-Fitzpatrick K, Zolfaghari R, Li L, Mas E, Lombardo D, Morel DW, Fisher EA: Pancreatic carboxyl ester lipase: a circulating enzyme that modifies normal and oxidized lipoproteins in vitro. J Clin Invest 1996, 97:1696-1704.
29. Chao FF, Blanchette-Mackie EJ, Dickens BF, Gamble W, Kruth HS: Development of unesterified cholesterol-rich lipid particles in atherosclerotic lesions of WHHL and cholesterol-fed NZW rabbits. J Lipid Res 1994, 35:71-83.
30. Schwenke DC: Selective increase in cholesterol at atherosclerosis-susceptible aortic sites after short-term cholesterol feeding. Arterioscler Thromb Vasc Biol 1995, 15:1928-37.
31. Tangirala RK, Jerome WG, Jones NL, Small DM, Johnson WJ, Glick JM, Mahlberg FH, Rothblat GH: Formation of cholesterol monohydrate crystals in macrophage-derived foam cells. J Lipid Res 1994, 35:93-104.
32. Johnson WJ, Warner GJ, Yancey PG, Rothblat GH: Lysosomal metabolism of lipids. Subcellular Biochem 1996, 27:239-293. Review of metabolism of lipids by lysosomes showing these organelles are important determinants of cholesterol trafficking in cells.
33. Klinkner AM, Waites CR, Kerns WD, Bugelski PJ: Evidence of foam cell and cholesterol crystal formation in macrophages incubated with oxidized LDL by fluorescence and electron microscopy. J Histochem Cytochem 1995, 43:1071-1978.
34. Sarig S, Weiss TA, Katz I, Kahana F, Azoury R, Okon E, Kruth HS: Detection of cholesterol associated with calcium mineral using confocal fluorescence microscopy. Lab Invest 1994, 71:782-787.
35. Demer LL: Lipid hypothesis of cardiovascular calcification. Circulation 1997, 95:297-298. Review of evidence implicating lipids as a precursor state for subsequent cardiovascular calcification.
36. Vyavahare N, Hirsch D, Lerner E, Baskin JZ, Schoen FJ, Bianco R, Kruth HS, Zand R, Levy RJ: Prevention of bioprosthetic heart valve calcification by ethanol preincubation. Efficacy and mechanisms. Circulation 1997, 95:479-488.
37. Hoff HF, Hoppe G: Structure of cholesterol-containing particles accumulating in atherosclerotic lesions and the mechanisms of their derivation. Curr Opin Lipidol 1995, 6:317-325.
38. Guyton JR, Klemp KF: Development of the lipid-rich core in human atherosclerosis. Arterioscler Thromb Vasc Biol 1996, 16:4-11. Review of evidence that extracellular deposition of lipid is a primary factor in the development of the critical lipid core region of atherosclerotic lesions.
39. Williams KJ, Tabas I: The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995, 15:551-561.
40. Kruth HS: Cholesterol deposition in atherosclerotic lesions. Subcellular Biochem 1997, 28:319-362. Review of the lipid particles in lesions and the processes that lead to deposition of cholesterol in atherosclerotic lesions.
41. Myers JN, Tabas I, Jones NL, Maxfield FR: β-very-low-density lipoprotein is sequestered in surface-connected tubules in mouse peritoneal macrophages. J Cell Biol 1993, 123:1389-1402.
42. Mamo JCL, Elsegood CL, Gennat HC, Yu K: Degradation of chylomicron remnants by macrophages occurs via phagocytosis. Biochemistry 1996, 35:10210-10214.
43. Fogelman AM, Shechter I, Seager J, Hokom M, Child JS, Edwards PA: Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci USA 1980, 77:2214-2218.
44. Khoo JC, Miller E, McLoughlin P, Steinberg D: Enhanced macrophage uptake of low density lipoprotein after self-aggregation. Arteriosclerosis 1988, 8:348-358.
45. Tertov VV, Sobenin IA, Gabbasov ZA, Popov EG, Orekhov AN: Lipoprotein aggregation is an essential condition of intracellular lipid accumulation caused by modified low density lipoproteins. Biochem Biophys Res Commun 1989, 163:489-494.
46. Kruth HS, Skarlatos SI, Lilly K, Chang J, Ifrim I: Sequestration of acetylated LDL and cholesterol crystals by human monocyte-derived macrophages. J Cell Biol 1995, 129:133-145.
47. Brown MS, Goldstein JL: Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Ann Rev Biochem 1983, 52:223-261.
48. Oram JF, Yokoyama S: Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res 1996, 37:2473-2491. Review of the functions of lipid-poor (free) apolipoproteins in cellular cholesterol efflux and the defect in this process shown by Tangier disease fibroblasts.
49. Yancey PG, Bielicki JK, Johnson WJ, Lund-Katz S, Palgunachari MN, Anantharamaiah GM, Segrest JP, Phillips MC, Rothblat GH: Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides. Biochem 1995, 34:7955-7965
50. Mazzone T, Reardon C: Expression of heterologous human apolipoprotein E by J774 macrophages enhances cholesterol efflux to HDL3. J Lipid Res 1994, 35:1345-1353.
51. Zhang WY, Gaynor PG, Kruth HS: Apolipoprotein E produced by human monocyte-derived macrophages mediates cholesterol efflux that occurs in the absence of added cholesterol acceptors. J Biol Chem 1996, 271:28641-28646. This report shows that human monocyte-macrophages have the capacity to efflux cholesterol through an autocrine mechanism dependent on macrophage apoE secretion. Thus, monocyte-macrophages in atherosclerotic lesions have the potential to excrete cholesterol independently of plasma-derived HDL. The finding may explain why transgenic expression of apoE in macrophages shows an anti-atherogenic effect (see Shimano et al. J Clin Invest 1995, 95:469-476 and Bellosta et al. J Clin Invest 1995, 96:2170-2179).
52. Smith JD, Miyata M, Ginsberg M, Grigaux C, Shmookler E, Plump AS: Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors. J Biol Chem 1996, 271:30647-30655. Reports evidence that macrophage-derived apoE can mediate cholesterol efflux. In addition, this study shows a cAMP-dependent step critical to efflux in mouse macrophage cells that appears to involve enhanced apoE binding.
53. Lindstedt L, Lee M, Castro GR, Fruchart JC, Kovanen PT: Chymase in exocytosed rat mast cell granules effectively proteolyzes apolipoprotein Al-containing lipoproteins, so reducing the cholesterol efflux-inducing ability of serum and aortic intimal fluid. J Clin Invest 1996, 97:2174-2182. Report of a novel mechanism that may impede cholesterol efflux from macrophages. This study demonstrates that mast cell-derived chymase can interfere with the cholesterol acceptor function of HDL by proteolyzing its apoA-l. It will be interesting to learn whether other lesion proteases besides chymase (e.g. metalloproteinases) show a similar anti-HDL effect.
54. Bjorkhem I, Andersson O, Diczfalusy U, Sevastik B, Xiu RJ, Duan C, Lund E: Atherosclerosis and sterol 27-hydroxylase: evidence for a role of this enzyme in elimination of cholesterol from human macrophages. Proc Natl Acad Sci U S A 1994, 91:8592-8596.
55. Lund E, Andersson O, Zhang J, Babiker A, Ahlborg G, Diczfalusy U, Einarsson K, Sjovall J, Bjorkhem I: Importance of a novel oxidative mechanism for elimination of intracellular cholesterol in humans. Arterioscler Thromb Vasc Biol 1996, 16:208-212.
56. Diczfalusy U, Lund E, Lutjohann D, Bjorkhem I: Novel pathways for elimination of cholesterol by extrahepatic formation of side-chain oxidized oxysterols. Scand J Clin Lab Invest 1996, 226(suppl):9-17.
57. Carpenter KL, Taylor SE, VanDer Veen C, Williamson BK, Ballantine JA, Mitchinson MJ: Lipids and oxidised lipids in human atherosclerotic lesions at different stages of development. Biochim Biophys Acta 1995, 1256:141-150.
58. Hulten LM, Lindmark H, Diczfalusy U, Bjorkhem I, Ottosson M, Liu Y, Bondjers G, Wiklund O: Oxysterols present in atherosclerotic tissue decrease the expression of lipoprotein lipase messenger RNA in human monocyte-derived macrophages. J Clin Invest 1996, 97:461-468.
59. Gelissen IC, Brown AJ, Mander EL, Kritharides L, Dean RT, Jessup W: Sterol efflux is impaired from macrophage foam cells selectively enriched with 7-ketocholesterol. J Biol Chem 1996, 271:17852-17860. Demonstrates that 7-ketocholesterol, a component of oxidized LDL, can impair cholesterol efflux from macrophages that have accumulated this oxysterol.
60. Maor I, Mandel H, Aviram M: Macrophage uptake of oxidized LDL inhibits lysosomal sphingomyelinase, thus causing the accumulation of unesterified cholesterol-sphingomyelin-rich particles in the lysosomes. A possible role for 7-Ketocholesterol. Arterioscler Thromb Vasc Biol 1995, 15:1378-1387.
61. Hsu HY, Nicholson AC, Pomerantz KB, Kaner RJ, Hajjar DP: Altered cholesterol trafficking in herpes virus-infected arterial cells. Evidence for viral protein kinase-mediated cholesterol accumulation. J Biol Chem 1995, 270:19630-19637.
62. Maziere C, Barbu V, Auclair M, Maziere JC: Interleukin 1 stimulates cholesterol esterification and cholesterol deposition in J774 monocytes-macrophages. Biochim Biophys Acta 1996, 1300:30-34.
63. Taniguchi S, Yanase T, Kobayashi K, Takayanagi H, Nawata H: Dehydroepiandrosterone arkedly inhibits the accumulation of cholesteryl ester in mouse macrophage J774-1 cells. Atherosclerosis 1996, 126:143-154.
64. Ball RY, Bindman JP, Carpenter KL, Mitchinson MJ: Oxidized low density lipoprotein induces cerold accumulation by murine peritoneal macrophages in vitro. Atherosclerosis 1986, 60:173-181.
65. Gerrity RG: The role of the monocyte in atherogenesis: II. Migration of foam cells from atherosclerotic lesions. Am J Pathol 1981, 103:191-200.
66. Nielsen LB: Transfer of low density lipoprotein into the arterial wall and risk of atherosclerosis. Atherosclerosis 1996, 123:1-15. Review of factors that determine entry of LDL into the arterial wall.
67. Bjornheden T, Babyi A, Bondjers G, Wiklund O: Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 1996, 123:43-56.
68. Juul K, Nielsen LB, Munkholm K, Stender S, Nordestgaard BG: Oxidation of plasma low-density lipoprotein accelerates its accumulation and degradation in the arterial wall in vivo. Circulation 1996, 94:1698-1704.